Trial · NCT04354259
Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19
NCT04354259, Phase 2, Completed, University Health Network, Toronto
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19. Trials, record NCT04354259. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04354259
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19
- NCT number
- NCT04354259
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 157 participants, actual
- Lead sponsor
- University Health Network, Toronto
- Conditions
- Sars-CoV2, Covid-19
- Interventions
- Peginterferon Lambda-1A, placebo
- First posted
- 2020-04-21
- Last updated
- 2023-12-13
Source ClinicalTrials.gov
Registered outcomes46
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cohort A (Ambulatory) - Proportion swab negative at day 7 (Primary efficacy endpoint) | At day 7 | The proportion of participants with negative SARS-CoV-2 RNA on nasopharyngeal swab. |
| Primary | Cohort A (Ambulatory) - Treatment-emergent and treatment related serious adverse events (Primary Safety Endpoint) | Day 0 to Day 28 | The rate of treatment-emergent and treatment-related serious adverse events (SAEs) |
| Primary | Cohort B (Hospitalized) - Ordinal Scale (Primary Efficacy Endpoint) | At Day 14 | Clinical status on an ordinal scale at Day 14 |
| Primary | Cohort B (Hospitalized) - treatment-emergent and treatment-related serious adverse events (Primary Safety Endpoint) | Day 0 to Day 28 | The rate of treatment-emergent and treatment-related serious adverse events (SAEs) |
| Secondary | Cohort A (Ambulatory) - Symptom Resolution (Clinical Outcome #1) | Day 0 to Day 14 | Time to resolution of symptoms (fever, cough, diarrhea) |
| Secondary | Cohort A (Ambulatory) - Symptom severity scores (Clinical Outcome #2) | Day 0 to Day 7 | Change in relative categorical symptom scores (respiratory, gastrointestinal, fever) - none, mild, moderate, severe and no change, worse, better |
| Secondary | Cohort A (Ambulatory) - Hospitalization (Clinical Outcome #3) | Day 0 to Day 14 | Proportion with need for hospital admission |
| Secondary | Cohort A (Ambulatory) - Adverse and serious adverse events (Clinical Outcome #4) | Day 0 to Day 14 | Adverse events and serious adverse events |
| Secondary | Cohort A (Ambulatory) - Swab negative at day 3 (Virologic/Immunological Outcome #1) | At Day 3 | Proportion negative for SARS-CoV-2 RNA by nasopharyngeal swab |
| Secondary | Cohort A (Ambulatory) - Time RNA negativity (Virologic/Immunological Outcome #2) | Day 0 to Day 14 | Time to SARS-CoV-2 RNA negativity on mid-turbinate nasal swab or saliva |
1 to 10 of 46Source ClinicalTrials.gov
See all 46 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04354259
GET https://conductscience.org/api/trials/v1/NCT04354259/registered?page=2